A new biotechnology company being launched out of Accelerator Corp., a business incubator in Seattle, is seeking to commercialize technology developed at Washington State University. Commercializing university research is not unusual for a start-up, except that this time, the biotech coming out of Pullman is expected to lead to cancer treatment for humans. This is a first for the landgrant university, whose traditional areas of expertise are in agricultural, veterinary and bioenergy sciences rather than human-based biomedical science. The technology is expected to yield therapies that arrest the spread of cancerous tumors. Research director for the start-up company, Recodagen, will be J. Suzanne Lindsey, the WSU researcher who first developed the technology. Recodagen has raised an undisclosed amount of initial seed funding, making it the first venture-funded start-up to come out of WSU's technology licensing program.